Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

BOSTON, Sept. 01, 2022 – Paratek Pharmaceuticals (Nasdaq: PRTK) announced President Adam Woodrow will speak at the H.C. Wainwright 24th Annual Global Investment Conference from Sept. 12-14. The conference will feature a virtual fireside chat accessible on-demand starting Sept. 12 at 7 a.m. ET. Paratek specializes in developing life-saving therapies, with its lead product NUZYRA® approved for treating bacterial pneumonia and skin infections. The company also conducts a Phase 2b study for NUZYRA targeting non-tuberculous mycobacterial pulmonary disease, estimating a $1 billion market opportunity.

BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Paratek President and Chief Commercial Officer Adam Woodrow will participate in a virtual fireside chat at the H.C. Wainwright 24^th Annual Global Investment Conference. The hybrid conference will be held from Sept. 12-14, with in-person participation held at the Lotte New York Palace Hotel.

Mr. Woodrow’s event will be available to view on-demand at: https://journey.ct.events/view/50615e23-aa8f-4cbd-b346-07b27991853f and under "Presentations & Events" in the Investors section of the company's website at https://www.paratekpharma.com/investor-relations beginning Sept. 12 at 7 a.m. ET and for the next 90 days.

Members of Paratek's senior management team will be available for virtual one-on-one meetings on Sept. 12.

About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.

The company’s lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, non-tuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.

Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

In 2019, Paratek was awarded a contract from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), now valued at up to $304 million, to support the development of omadacycline for pulmonary anthrax and the U.S.-based commercial manufacturing of NUZYRA.

For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter.

Forward Looking Statements
This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2021 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

For Investors:

Hans Vitzthum LifeSci Advisors ir@ParatekPharma.com

Phone: 617-430-7578

For Media:

Christine Fanelle Scient PR Christine@scientpr.com Phone: 215-595-5211

FAQ

What is the schedule for the H.C. Wainwright 24th Annual Global Investment Conference involving PRTK?

The conference will take place from September 12-14, 2022, and will include a virtual fireside chat with Adam Woodrow on September 12.

Where can I view the presentation by Adam Woodrow for Paratek Pharmaceuticals?

The presentation will be available on-demand starting September 12 at 7 a.m. ET on the company's investor relations website.

What is NUZYRA® and what conditions does it treat?

NUZYRA® is an antibiotic developed by Paratek for treating community-acquired bacterial pneumonia and acute bacterial skin infections.

What market opportunity does Paratek see for NUZYRA in non-tuberculous mycobacterial pulmonary disease?

Paratek estimates a $1 billion addressable market for NUZYRA in treating non-tuberculous mycobacterial pulmonary disease.

What are the key developments surrounding Paratek Pharmaceuticals as of September 2022?

Paratek announced participation in a major investment conference, highlighted its lead product NUZYRA®, and discussed ongoing studies in new therapeutic areas.